TTFields enhance downstream antitumor immune response1
TTFields-mediated cell disruption activates the immune system and triggers an antitumor cell response downstream1
TTFields lead to the onset of aneuploidy, ER stress, and low intracellular ATP levels, upregulating an autophagic response in cancer cells, as demonstrated in preclinical models.2
Watch below to see how TTFields enhance the downstream antitumor immune response
See the enhanced effects of TTFields when used with a PD-1 inhibitor
See preclinical dataSee how TTFields therapy also impacts DNA damage repair in cancer cells
ExploreReferences: 1. Voloshin T, Kaynan N, Davidi S, et al. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunol Immunother. 2020;69(7):1191-1204. doi:10.1007/s00262-020-02534-7 2. Shteingauz A, Porat Y, Voloshin T, et al. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields). Cell Death Dis. 2018;9:1074. doi:10.1038/s41419-018-1085-9